Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Clioquinol - Gerolymatos Group/Alterity Therapeutics

Drug Profile

Clioquinol - Gerolymatos Group/Alterity Therapeutics

Alternative Names: Chloroiodoquine; Gero-46; Iodochlorhydroxyquin; Iodochlorhydroxyquinoline; PBT-1

Latest Information Update: 05 Nov 2021

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Gerolymatos Group; Prana Biotechnology
  • Class Antibacterials; Antidementias; Antifungals; Antiprotozoals; Hydroxyquinolines; Ionophores; Small molecules
  • Mechanism of Action Chelating agents
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Discontinued Alzheimer's disease

Most Recent Events

  • 08 Apr 2019 Prana Biotechnology is now called Alterity Therapeutics
  • 11 Apr 2005 Discontinued - Phase-II for Alzheimer's disease in Australia (unspecified route)
  • 04 Jan 2005 Prana Biotechnology has received a CTA from the UK MHRA to initiate a phase II/III trial
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top